2. Academic Validation
  3. Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders

Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders

  • J Med Chem. 2021 Oct 14;64(19):14773-14792. doi: 10.1021/acs.jmedchem.1c01356.
Huji Turdi,  Hannguang Chao,  Jon J Hangeland,  Saleem Ahmad,  Wei Meng,  Robert Brigance,  Guohua Zhao,  Wei Wang,  Fang Moore,  Xiang-Yang Ye,  Arvind Mathur,  Xiaoping Hou,  James Kempson,  Dauh-Rurng Wu,  Yi-Xin Li,  Anthony V Azzara,  Zhengping Ma,  Ching-Hsuen Chu,  Luping Chen,  Mary Jane Cullen,  Suzanne Rooney,  Susan Harvey,  Lisa Kopcho,  Reshma Panemangelor,  Lynn Abell,  Kevin O'Malley,  William J Keim,  Elizabeth Dierks,  Shu Chang,  Kimberly Foster,  Atsu Apedo,  David Harden,  Marta Dabros,  Qi Gao,  Mary Ann Pelleymounter,  Jean M Whaley,  Jeffrey A Robl,  Dong Cheng,  R Michael Lawrence,  Pratik Devasthale
PMID: 34613725 DOI: 10.1021/acs.jmedchem.1c01356
Abstract

MGAT2 inhibition is a potential therapeutic approach for the treatment of metabolic disorders. High-throughput screening of the BMS internal compound collection identified the aryl dihydropyridinone compound 1 (hMGAT2 IC50 = 175 nM) as a hit. Compound 1 had moderate potency against human MGAT2, was inactive vs mouse MGAT2 and had poor microsomal metabolic stability. A novel chemistry route was developed to synthesize aryl dihydropyridinone analogs to explore structure-activity relationship around this hit, leading to the discovery of potent and selective MGAT2 inhibitors 21f, 21s, and 28e that are stable to liver microsomal metabolism. After triaging out 21f due to its inferior in vivo potency, pharmacokinetics, and structure-based liabilities and tetrazole 28e due to its inferior channel liability profile, 21s (BMS-963272) was selected as the clinical candidate following demonstration of on-target weight loss efficacy in the diet-induced obese mouse model and an acceptable safety and tolerability profile in multiple preclinical species.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z